The U.S. Food and Drug Administration (FDA) has announced the approval of Qfitlia (fitusiran), a treatment designed to ...

Factor XI Inhibitors are the alternative to DOACs, which are highly effective at preventing strokes. However, their bleeding risks often limit their use, especially in high-risk patients.

Sanofi has received FDA approval for Qfitlia, its innovative hemophilia therapy that represents the first antithrombin-lowering treatment for hemophilia A or B patients with or without inhibitors ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Platelet spreading and clot contraction are controlled by different pathways. This discovery leads to safer treatments for ...

When skin is cut or damaged, tiny cell fragments circulating in the blood, called platelets, arrive at the injury and spread out to stop the blood from leaking out. Once enough layers of platelets ...

When skin is cut or damaged, tiny cell fragments circulating in the blood, called platelets, arrive at the injury and spread out to stop the blood ...

Until recently, researchers believed that platelet spreading and clot contraction were controlled by the same pathway. However a recent study from Thomas Jefferson University researchers challenges ...

Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...

Our blood consists of many cell types that develop through different stages from a precursor type -- the blood stem cell. An international research team has now investigated the developmental pathways ...

Hemophilia is a genetic bleeding disorder that prevents blood from properly clotting. Severe bleeding from minor injuries or surgery can occur. Low levels or the absence of some proteins ...

They then narrowed their list of proteins to 198 with well-known roles in inflammatory and clotting processes following traumatic injury. Patients who received plasma had a distinct proteomic ...